Literature DB >> 11087860

A role for ubiquitin ligase recruitment in retrovirus release.

B Strack1, A Calistri, M A Accola, G Palu, H G Gottlinger.   

Abstract

Retroviral Gag polyproteins have specific regions, commonly referred to as late assembly (L) domains, which are required for the efficient separation of assembled virions from the host cell. The L domain of HIV-1 is in the C-terminal p6(gag) domain and contains an essential P(T/S)AP core motif that is widely conserved among lentiviruses. In contrast, the L domains of oncoretroviruses such as Rous sarcoma virus (RSV) have a more N-terminal location and a PPxY core motif. In the present study, we used chimeric Gag constructs to probe for L domain activity, and observed that the unrelated L domains of RSV and HIV-1 both induced the appearance of Gag-ubiquitin conjugates in virus-like particles (VLP). Furthermore, a single-amino acid substitution that abolished the activity of the RSV L domain in VLP release also abrogated its ability to induce Gag ubiquitination. Particularly robust Gag ubiquitination and enhancement of VLP release were observed in the presence of the candidate L domain of Ebola virus, which contains overlapping P(T/S)AP and PPxY motifs. The release defect of a minimal Gag construct could also be corrected through the attachment of a peptide that serves as a physiological docking site for the ubiquitin ligase Nedd4. Furthermore, VLP formation by a full-length Gag polyprotein was sensitive to lactacystin, which depletes the levels of free ubiquitin through inhibition of the proteasome. Our findings suggest that the engagement of the ubiquitin conjugation machinery by L domains plays a crucial role in the release of a diverse group of enveloped viruses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087860      PMCID: PMC27178          DOI: 10.1073/pnas.97.24.13063

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Comparison of the nonstructural protein, NS3, of tick-borne and insect-borne orbiviruses.

Authors:  S R Moss; L D Jones; P A Nuttall
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

2.  Localization of the non-structural protein NS3 in bluetongue virus-infected cells.

Authors:  A D Hyatt; A R Gould; B Coupar; B T Eaton
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

3.  Release of bluetongue virus-like particles from insect cells is mediated by BTV nonstructural protein NS3/NS3A.

Authors:  A D Hyatt; Y Zhao; P Roy
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

4.  Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain.

Authors:  M Treier; L M Staszewski; D Bohmann
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

5.  An assembly domain of the Rous sarcoma virus Gag protein required late in budding.

Authors:  J W Wills; C E Cameron; C B Wilson; Y Xiang; R P Bennett; J Leis
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  Functional association of cyclophilin A with HIV-1 virions.

Authors:  M Thali; A Bukovsky; E Kondo; B Rosenwirth; C T Walsh; J Sodroski; H G Göttlinger
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

7.  Ubiquitin in avian leukosis virus particles.

Authors:  D Putterman; R B Pepinsky; V M Vogt
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

8.  The release of bluetongue virus from infected cells and their superinfection by progeny virus.

Authors:  A D Hyatt; B T Eaton; S M Brookes
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

9.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.

Authors:  L J Parent; R P Bennett; R C Craven; T D Nelle; N K Krishna; J B Bowzard; C B Wilson; B A Puffer; R C Montelaro; J W Wills
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  151 in total

Review 1.  Ubiquitin in retrovirus assembly: actor or bystander?

Authors:  V M Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  Ubiquitin is part of the retrovirus budding machinery.

Authors:  A Patnaik; V Chau; J W Wills
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

3.  Insertion of capsid proteins from nonenveloped viruses into the retroviral budding pathway.

Authors:  N K Krishna; J W Wills
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 4.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

5.  In vivo interference of Rous sarcoma virus budding by cis expression of a WW domain.

Authors:  Akash Patnaik; John W Wills
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Structure and functional interactions of the Tsg101 UEV domain.

Authors:  Owen Pornillos; Steven L Alam; Rebecca L Rich; David G Myszka; Darrell R Davis; Wesley I Sundquist
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

Review 7.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Role of ESCRT-I in retroviral budding.

Authors:  Juan Martin-Serrano; Trinity Zang; Paul D Bieniasz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process.

Authors:  M Tritel; M D Resh
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

10.  Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins.

Authors:  Juan Martin-Serrano; Anton Yarovoy; David Perez-Caballero; Paul D Bieniasz; Anton Yaravoy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.